Besins Hlthcare patents expiration
1. Androgel patents expiration
ANDROGEL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6503894 | BESINS HLTHCARE | Pharmaceutical composition and method for treating hypogonadism |
Aug, 2020
(3 years ago) | |
| US9125816 | BESINS HLTHCARE | Pharmaceutical composition and method for treating hypogonadism |
Aug, 2020
(3 years ago) | |
| US9132089 | BESINS HLTHCARE | Pharmaceutical composition and method for treating hypogonadism |
Aug, 2020
(3 years ago) | |
|
US6503894 (Pediatric) | BESINS HLTHCARE | Pharmaceutical composition and method for treating hypogonadism |
Mar, 2021
(3 years ago) | |
|
US9125816 (Pediatric) | BESINS HLTHCARE | Pharmaceutical composition and method for treating hypogonadism |
Mar, 2021
(3 years ago) | |
|
US9132089 (Pediatric) | BESINS HLTHCARE | Pharmaceutical composition and method for treating hypogonadism |
Mar, 2021
(3 years ago) | |
| US8446138 | BESINS HLTHCARE | Stability compensation circuit and DC-DC converter including the same |
Oct, 2026
(2 years from now) | |
| US8466137 | BESINS HLTHCARE | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | |
| US8466138 | BESINS HLTHCARE | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | |
| US8741881 | BESINS HLTHCARE | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | |
| US8754070 | BESINS HLTHCARE | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | |
| US8729057 | BESINS HLTHCARE | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | |
| US8759329 | BESINS HLTHCARE | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | |
| US8466136 | BESINS HLTHCARE | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | |
| US8486925 | BESINS HLTHCARE | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 26 September, 2003
Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone
Dosage: GEL;TRANSDERMAL; GEL, METERED;TRANSDERMAL
More Information on Dosage
ANDROGEL family patents
